NYSE · Healthcare
BOSTON SCIENTIFIC CORP (BSX)
As-reported financials and recent SEC filings for BOSTON SCIENTIFIC CORP, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$20.07B
Net income
$2.89B
Net margin
14.4%
Diluted EPS
$1.94
ROE
11.8%
P/E (TTM)
19.6×
Market cap
$69.72B
Debt / equity
0.5×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $20.07B | $16.75B | $14.24B | $12.68B | $11.89B |
| Gross profit | $13.85B | $11.49B | $9.89B | $8.73B | $8.18B |
| Operating income | $3.61B | $2.60B | $2.34B | $1.65B | $1.20B |
| Net income | $2.89B | $1.85B | $1.59B | $698.0M | $1.04B |
| Diluted EPS | $1.94 | $1.25 | $1.07 | $0.45 | $0.69 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-01
View on EDGAR →42026-05-21
View on EDGAR →42026-05-21
View on EDGAR →42026-05-21
View on EDGAR →SD2026-05-21
View on EDGAR →8-K2026-05-18
View on EDGAR →8-K2026-05-18
View on EDGAR →42026-05-11
View on EDGAR →Go deeper on BSX
Search BOSTON SCIENTIFIC CORP’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.